ResMed (NYSE:RMD) Given New $250.00 Price Target at Wells Fargo & Company

ResMed (NYSE:RMD) had its target price hoisted by Wells Fargo & Company from $215.00 to $250.00 in a research note issued to investors on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the medical equipment provider’s stock.

RMD has been the subject of a number of other reports. Citigroup reissued a “neutral” rating on shares of ResMed in a report on Thursday, September 10th. Royal Bank Of Canada increased their price objective on ResMed from $262.00 to $288.00 and gave the company an “outperform” rating in a research note on Friday. Jefferies Financial Group dropped their price objective on ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a research report on Friday, July 10th. Mizuho set a $270.00 target price on shares of ResMed in a research note on Friday. Finally, Weiss Ratings upgraded shares of ResMed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Seven research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, ResMed has a consensus rating of “Hold” and a consensus target price of $253.69.

ResMed Stock Down 8.7%

RMD stock opened at $230.76 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.10 and a quick ratio of 2.42. The company’s 50 day simple moving average is $231.87 and its 200-day simple moving average is $225.43. ResMed has a 12 month low of $180.26 and a 12 month high of $277.67. The firm has a market capitalization of $32.45 billion, a PE ratio of 21.02, a P/E/G ratio of 1.55 and a beta of 0.75.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $0.24. The firm had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.39 billion. ResMed had a return on equity of 25.90% and a net margin of 27.79%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.55 EPS. Equities analysts expect that ResMed will post 12.11 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Thursday, November 12th will be given a $0.66 dividend. This represents a $2.64 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 12th. ResMed’s dividend payout ratio (DPR) is 25.31%.

Insider Activity at ResMed

In other news, CEO Michael J. Farrell sold 4,991 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $205.69, for a total value of $1,026,598.79. Following the transaction, the chief executive officer directly owned 466,256 shares in the company, valued at $95,904,196.64. This trade represents a 1.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of ResMed stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director directly owned 52,773 shares in the company, valued at $11,873,925. This represents a 13.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 24,343 shares of company stock worth $5,396,098. 0.58% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Bell Investment Advisors Inc purchased a new position in shares of ResMed in the second quarter valued at $26,000. Trust Co. of Vermont acquired a new stake in ResMed during the 2nd quarter valued at $39,000. Kelleher Financial Advisors purchased a new stake in ResMed during the 2nd quarter worth $47,000. Provenance Wealth Advisors LLC purchased a new stake in ResMed during the 3rd quarter worth $55,000. Finally, Ballast Advisors LLC acquired a new position in ResMed in the 1st quarter worth $84,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

More ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Quarterly results exceeded expectations. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share versus the $2.67 consensus estimate, while revenue rose 5.9% year over year to $1.41 billion, ahead of the $1.39 billion forecast. ResMed fiscal first-quarter results
• Positive Sentiment: Profitability and demand trends improved. Sustained demand for sleep devices, productivity gains and gross-margin expansion supported the earnings beat. EPS increased from $2.55 in the year-ago quarter, and ResMed reported a 26.94% net margin. ResMed earnings and margin growth
• Positive Sentiment: Analysts raised price targets. RBC increased its target from $262 to $288 and assigned an “outperform” rating. KeyCorp raised its target from $267 to $277 with an “overweight” rating, while Wells Fargo lifted its target from $215 to $250 and maintained “equal weight.” Citigroup raised its target from $240 to $270 but retained a “neutral” rating. Analyst target changes
• Neutral Sentiment: ResMed declared a quarterly dividend of $0.66 per share, or $2.64 annualized, representing an approximately 1.1% yield. The dividend supports shareholder returns but is unlikely to be the primary near-term stock catalyst.
• Negative Sentiment: Full-year guidance was unchanged. The lack of an outlook increase may have disappointed investors who expected the earnings beat and improving margins to result in raised expectations. The neutral ratings from Citigroup and Wells Fargo may also limit the impact of the higher price targets. ResMed maintains prior guidance

About ResMed

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.